Coordinatore | UPPSALA UNIVERSITET
Organization address
address: SANKT OLOFSGATAN 10 B contact info |
Nazionalità Coordinatore | Sweden [SE] |
Totale costo | 7˙950˙621 € |
EC contributo | 6˙000˙000 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2009-single-stage |
Funding Scheme | CP-FP |
Anno di inizio | 2010 |
Periodo (anno-mese-giorno) | 2010-04-01 - 2013-03-31 |
# | ||||
---|---|---|---|---|
1 |
UPPSALA UNIVERSITET
Organization address
address: SANKT OLOFSGATAN 10 B contact info |
SE (UPPSALA) | coordinator | 1˙400˙000.00 |
2 |
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Organization address
address: CALLE SERRANO 117 contact info |
ES (MADRID) | participant | 850˙000.00 |
3 |
UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
CH (ZURICH) | participant | 550˙000.00 |
4 |
INSTITUT PASTEUR
Organization address
address: RUE DU DOCTEUR ROUX 25-28 contact info |
FR (PARIS CEDEX 15) | participant | 500˙000.00 |
5 |
SERVICIO MADRILENO DE SALUD
Organization address
address: PLAZA CARLOS TRIAS BERTRAN 7 contact info |
ES (MADRID) | participant | 500˙000.00 |
6 |
CARDIFF UNIVERSITY
Organization address
address: Newport Road 30-36 contact info |
UK (CARDIFF) | participant | 450˙000.00 |
7 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 350˙000.00 |
8 |
STATENS SERUM INSTITUT
Organization address
address: ARTILLERIVEJ 5 contact info |
DK (KOBENHAVN S) | participant | 350˙000.00 |
9 |
THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS
Organization address
address: NORTH STREET 66 COLLEGE GATE contact info |
UK (ST ANDREWS FIFE) | participant | 350˙000.00 |
10 |
THE UNIVERSITY OF SHEFFIELD
Organization address
address: FIRTH COURT WESTERN BANK contact info |
UK (SHEFFIELD) | participant | 350˙000.00 |
11 |
UNIVERSITY OF LEEDS
Organization address
address: WOODHOUSE LANE contact info |
UK (LEEDS) | participant | 350˙000.00 |
12 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'The aim of this proposal is to describe and predict the dynamics of antibiotic resistance development at the level of the drug target, the microbe and the host. That is, we want to generate the knowledge required to be able to connect resistance mechanism --> bacterial physiology and fitness --> bacterial survival within a host --> bacterial spread between hosts. To achieve this goal we will develop quantitative models that can capture these complex dynamics, obtain relevant parameter values and validate the models by testing them in suitable in vitro, animal models and in clinical settings. We will address three main areas (A-C) in 11 different work packages. A. Formation and emergence of resistant bacteria (WPs1-5). The rate of formation of resistant mutants is one major determinant that influences how rapidly resistant mutants will appear in response to antibiotic use. Depending on the type of resistance mechanism factors such as rates of mutation, recombination and transfer of plasmids will be important. In WPs 1-5 we will experimentally determine these rates for different combinations of bacterial species and resistance mechanisms. B. Survival and persistence of resistant strains (WPs 6-8). A key factor that affects the survival and persistence of resistant strains is the impact the particular resistance mechanism has on bacterial physiology, including bacterial growth rate and virulence. We want to determine the effect of various drug resistance mechanisms on cellular physiology and fitness to establish a link between the molecular alteration and potential effects at the cellular level. C. Transmission of resistant strains (WPs 9-11). Finally we want to understand and predict how resistance mechanisms (by their effect on bacterial physiology) influence the ability of the bacteria to be transmitted between hosts. Thus, we aim to generate both animal and clinical determinations of how resistance affects transmissibility and testable mathematical models.'